Association between genetic variants of EGF-containing fibulin-like extracellular matrix protein1 gene and sporadic breast cancer in a Chinese Han population

Purpose of investigation: To correlate serum CA125 at relapse with survival in ovarian cancer patients who achieved a complete response after primary cytoreduction and paclitaxel- and platinum-based chemotherapy. Materials and Methods: The study was conducted in 104 patients. Results: The 25%, 50%, and 75% quantiles of CA125 levels at relapse were 46, 118, and 190 U/ml. By log-rank test, survival after recurrence was related to consolidation treatment (p = 0.046), platinum-free interval (PFI) (p < 0.000005), number of recurrence sites (p = 0.03), treatment at recurrence (p = 0.002), and serum CA125 taking 118 U/ml as cut-off (p = 0.013). On multivariate analysis, consolidation treatment (p = 0.007), PFI (p = 0.0001), treatment at recurrence (p = 0.01), and serum CA125 taking 118 U/ml as cut-off (p =0.04) were independent prognostic variables for survival. Conclusions: Serum CA125 at relapse was an independent prognostic variable. Patients with serum CA125 >118 U/m had 1.943 higher risk of death than those with lower antigen value.

EFEMP1 gene; Single nucleotide polymorphism; Genetic susceptibility; Molecular biology; Breast cancer.

[1] Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D. M.: “Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008”. Int. J. Cancer, 2010, 127, 2893.

[2] Walsh T., King M.C.: “Ten genes for inherited breast cancer”. Cancer Cell, 2007, 11, 103.

[3] Pharoah P.D., Dunning A.M., Ponder B.A., Easton D.F.: “Association studies for finding cancer-susceptibility genetic variants”. Nat. Rev. Cancer, 2004, 4, 850.

[4] De Vega S., Iwamoto T., Yamada Y.: “Fibulins: multiple roles in matrix structures and tissue functions”. Cell. Mol. Life Sci., 2009, 66, 1890.

[5] Gallagher W.M., Currid C.A., Whelan L.C..: “Fibulins and cancer: friend or foe?” Trends Mol. Med., 2005, 11, 336.

[6] Albig A.R., Neil J.R., Schiemann W.P.: “Fibulins 3 and 5 antagonize tumor angiogenesis in vivo”. Cancer Res., 2006, 66, 2621.

[7] Yue W., Dacic S., Sun Q., Landreneau R., Guo M., Zhou W., et al.: “Frequent inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter hypermethylation”. Clinical Cancer Res., 2007, 13, 4336.

[8] Nomoto S., Kanda M., Okamura Y., Nishikawa Y., Qiyong L., Fujii T., et al.: “Epidermal growth factor-containing fibulin-like extracellular matrix protein 1, EFEMP1, a novel tumor-suppressor gene detected in hepatocellular carcinoma using double combination array analysis”. Ann. Surg. Oncol., 2010, 17, 923.

[9] En-lin S., Sheng-guo C., Hua-qiao W.: “The expression of EFEMP1 in cervical carcinoma and its relationship with prognosis”. Gynecol. Oncol., 2010, 117, 417.

[10] Kim Y.J., Yoon H.Y., Kim S.K., Kim Y.W., Kim E.J., Kim I.Y., Kim, W.J.: “EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling”. Clin. Cancer Res., 2011, 1, 4523.

[11] Zhang Y., Wang R., Song H., Huang G., Yi J., Zheng Y., et al.: “Methylation of multiple genes as a candidate biomarker in nonsmall cell lung cancer”. Cancer Lett., 2011, 303, 21.

[12] Hwang C.F., Chien C.Y., Huang S.C., Yin Y.F., Huang C.C., Fang F.M., et al.: “Fibulin-3 is associated with tumour progression and a poor prognosis in nasopharyngeal carcinomas and inhibits cell migration and invasion via suppressed AKT activity”. J. Pathol., 2010, 222, 367.

[13] Sadr-Nabavi A., Ramser J., Volkmann J., Naehrig J., Wiesmann F., Betz B., et al.: “Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker”. Int. J. Cancer, 2009, 124, 1727

[14] Davidson B., Stavnes H.T., Holth A., Chen X., Yang Y., Shih I.M., et al.: “Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions”. J. Cell. Mol. Med., 2011, 15, 535.

[15] Seeliger H., Camaj P., Ischenko I., Kleespies A., De Toni E.N., Thieme S.E., et al.: “EFEMP1 expression promotes in vivo tumor growth in human pancreatic adenocarcinoma”. Mol. Cancer Res., 2009, 7, 189.

[16] O’Donnell M.J., Little D.P., Braun A.: “MassArray as an enabling technology for the industrial-scale analysis of DNA”. Genetic Engineering News, 1997, 17 ,39.

[17] Shastry B.S.: “SNP alleles in human disease and evolution”. J. Hum. Genet., 2002, 47, 561.

[18] Chorev M., Carmel L.: “The function of introns”. Front Genet., 2002, 3, 55.

[19] Mattick J.S.: “Introns: evolution and function”. Curr. Opin. Genet. Dev., 1994, 4, 823.

[20] Shriner D., Adeyemo A., Gerry N. P., Herbert A., Chen G., Doumatey A., et al.: “Transferability and fine-mapping of genome-wide associated loci for adult height across human populations”. PLoS One, 2009, 4, e8398..

[21] Croteau-Chonka D.C., Marvelle A.F., Lange E.M., Lee N.R., Adair, L.S., Lange L.A., et al.: “Genome-wide association study of anthropometric traits and evidence of interactions with age and study year in Filipino women”. Obesity, 2011, 19, 1019.

[22] Zhao J., Li M., Bradfield J.P., Zhang H., Mentch F.D., Wang K., et al.: “The role of height-associated loci identified in genome wide association studies in the determination of pediatric stature”. BMC Med. Gen., 2010, 11, 96.

[23] Weedon M.N., Frayling T.M.: “Reaching new heights: insights into the genetics of human stature”. Trends Genet., 2008, 24, 595.